YOLFTbeta
Hangzhou Minsheng Healthcare Co Ltd

Hangzhou Minsheng Healthcare Co Ltd

301507 · SHE · Healthcare / Drug Manufacturers - General

11.43CNY-0.23 (-1.97%)

Price History

Full chart

Market Stats

Previous Close11.66
Open11.77
Day Range11.37 – 11.78
52-Week Range11.40 – 19.02
Volume2.95M
Market Cap4.78B
P/E (TTM)40.67
Forward P/E0.00
EPS0.33
Dividend Yield1.12%
Beta0.53
50-Day Avg12.53
200-Day Avg13.89

About

Hangzhou Minsheng Healthcare Co., Ltd. engages in the research, development, production, and sale of vitamins and mineral supplements, OTC drugs, and healthy foods in China and internationally. The company offers healthy products, such as fish and algae oil gel candy, collagen peptide vitamin D calcium chewable tablets, blueberry lutein ester candy tablets, and probiotic solid beverage. It also provides multivitamin, vitamin, and zinc selenium with mineral tablets; and glucosamine chondroitin colostrum protein chewable, vitamin soft capsules and chewable, iron folic acid, melatonin, coenzyme soft capsules, and calcium magnesium vitamin D tablets. The company offers its products under the 21 SUPER-VITA brand name. Hangzhou Minsheng Healthcare Co., Ltd. was founded in 1926 and is based in Hangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMr. Haijun Zhang
  • Employees710
  • HeadquartersNo. 658, Bin'an Road, Hangzhou, China, 310051, China
  • Websitehttps://www.hzmsjk.com

Leadership

  • Mr. Haijun ZhangGM & Non-Independent Director · b. 1981
  • Mr. Wenjun ZhuFinancial Manager · b. 1988
  • Ms. Liyun LiuDeputy General Manager · b. 1978
  • Mr. Wenzhu ChenBoard Secretary · b. 1973
  • Ms. Suqing WangDeputy General Manager · b. 1982
  • Lu DongAccounting Supervisor

Financials

Income Statement

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue489.58M547.12M581.73M641.25M781.63M
Growth (%)-+11.75%+6.33%+10.23%+21.89%
Cost of Revenue167.88M215.99M220.64M283.62M382.22M
Gross Profit321.70M331.13M361.09M357.63M399.41M
Gross Margin65.71%60.52%62.07%55.77%51.10%
Operating Expense253.33M246.82M271.30M273.26M307.50M
Operating Income68.37M84.31M89.80M84.37M91.91M
Operating Margin13.97%15.41%15.44%13.16%11.76%
EBITDA-120.68M124.61M129.71M166.66M
EBITDA Margin-22.06%21.42%20.23%21.32%
Net Income70.22M79.01M85.63M91.83M118.79M
Net Income Margin14.34%14.44%14.72%14.32%15.20%
R&D24.07M27.17M29.56M23.98M26.08M
R&D as % of Total Revenue4.92%4.97%5.08%3.74%3.34%
Interest Expense507.53K317.15K106.77K62.36K56.74K
Interest Expense % of Total Revenue0.10%0.06%0.02%0.01%0.01%

Balance Sheet

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets681.49M765.29M1.65B1.74B2.02B
Total Liabilities166.37M171.16M174.75M213.76M298.60M
Total Equity515.12M594.13M1.47B1.53B1.60B
Cash22.32M47.34M428.30M338.73M289.40M

Cash Flow

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow44.31M95.31M108.15M108.46M177.17M
Capital Expenditure25.56M26.94M36.07M94.89M196.33M
Free Cash Flow18.75M68.37M72.08M13.57M-19.16M
Dividends Paid150.38M--35.66M35.55M
FCF to OCF42.32%71.73%66.65%12.51%-10.81%
Dividend Paid to FCF801.87%--262.71%-185.53%

Earnings

Report DateSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Apr 24, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------
EPS Actual0.030.010.170.050.030.020.180.060.090.010.180.06
Surprise------------
Timing------Pre-market-----

Key Statistics & Ratios

Market Cap4.78B
Enterprise Value3.94B
Trailing P/E40.67
Forward P/E0.00
Price / Sales5.60
Price / Book2.95
EPS0.33
Book Value4.55
Revenue (TTM)854.51M
Gross Profit (TTM)442.39M
EBITDA127.15M
Profit Margin14.02%
Operating Margin8.83%
Return on Equity7.15%
Return on Assets3.07%
Shares Outstanding356.55M
Shares Float108.29M
Beta0.53
Dividend Yield1.12%
Dividend Rate0.15
Payout Ratio44.37%

Dividends

20261×
0.15Jun 9, 2026
20251×
0.10Jun 20, 2025
20241×
0.10Jun 14, 2024